Veru Inc (NASDAQ:VERU) Expected to Announce Earnings of -$0.03 Per Share

Equities analysts predict that Veru Inc (NASDAQ:VERU) will post earnings of ($0.03) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Veru’s earnings. The highest EPS estimate is $0.00 and the lowest is ($0.05). Veru also posted earnings per share of ($0.03) during the same quarter last year. The business is scheduled to report its next earnings report on Wednesday, February 12th.

On average, analysts expect that Veru will report full year earnings of ($0.10) per share for the current year, with EPS estimates ranging from ($0.19) to ($0.02). For the next year, analysts expect that the business will report earnings of $0.05 per share. Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Veru.

Veru (NASDAQ:VERU) last posted its quarterly earnings results on Thursday, December 12th. The company reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05). The business had revenue of $8.73 million during the quarter, compared to the consensus estimate of $9.26 million. Veru had a negative net margin of 37.79% and a negative return on equity of 34.96%.

Several analysts have weighed in on the stock. Zacks Investment Research raised shares of Veru from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research note on Thursday, December 19th. ValuEngine raised shares of Veru from a “sell” rating to a “hold” rating in a research note on Friday, November 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $4.50 price target on shares of Veru in a research note on Friday, December 13th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $5.93.

In other Veru news, CEO Mitchell Shuster Steiner sold 25,000 shares of the business’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $2.27, for a total value of $56,750.00. 29.50% of the stock is currently owned by insiders.

Hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC purchased a new position in shares of Veru in the third quarter valued at about $25,000. Squarepoint Ops LLC purchased a new position in shares of Veru in the third quarter valued at about $39,000. Alpine Global Management LLC purchased a new position in shares of Veru in the fourth quarter valued at about $80,000. BlackRock Inc. increased its position in shares of Veru by 65.4% in the second quarter. BlackRock Inc. now owns 228,934 shares of the company’s stock valued at $487,000 after acquiring an additional 90,530 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Veru by 183.1% in the second quarter. Renaissance Technologies LLC now owns 262,160 shares of the company’s stock valued at $558,000 after acquiring an additional 169,550 shares during the period. Hedge funds and other institutional investors own 9.76% of the company’s stock.

Veru stock traded up $0.09 during mid-day trading on Friday, hitting $4.19. The company’s stock had a trading volume of 258,000 shares, compared to its average volume of 444,108. The company has a debt-to-equity ratio of 0.09, a current ratio of 1.20 and a quick ratio of 0.94. The stock has a market cap of $264.71 million, a price-to-earnings ratio of -22.05 and a beta of 0.53. The business has a 50 day moving average price of $2.99 and a 200-day moving average price of $2.29. Veru has a 12 month low of $1.18 and a 12 month high of $4.35.

About Veru

Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

Further Reading: Quiet Period

Get a free copy of the Zacks research report on Veru (VERU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.